Moderna Vaccine (.)
The American company Modern stated on Monday that laboratory studies indicated that your Covid-19 vaccine would continue to protect against the variants of coronavirus identified in the United Kingdom and South Africa, but “as a precaution” develop a booster formula against mutations.
“The study did not show any significant impact” on the level of neutralizing antibodies elicited against the UK variant, B.1.1.7.
In the analysis a six-fold reduction in antibody levels was observed with variant B.1.351 observed for the first time in South Africa, but it is believed that the levels are still above what is required for protection against Covid-19.
Therefore, a two-dose regimen is expected to protect against emerging strains detected to date, the company said. However, he added that this decrease opens the possibility that immunity is less durable against these variants.
“As we attempt to defeat the COVID-19 virus, which has created a global pandemic, we believe it is imperative to be proactive as the virus evolves. We are encouraged by these new data, which reinforces our confidence that Moderna’s COVID-19 vaccine should be protective against these newly detected variants, ”said Stéphane Bancel, CEO of Moderna.
“Out of abundance of caution and taking advantage of the flexibility of our mRNA platform, we are advancing an emerging variant boost candidate against the variant first identified in South Africa. in the clinic to determine if it will be more effective to reinforce the titles against this and potentially future variants ”, added the executive.
Previously, scientists had explained that the formulas developed by mRNA technology are easy to modify if deemed necessary, although these would require a new approval by the health authorities.
News in development